Second phase of induction

PreclinicalSmall molecule

FFederal Research Institute of Pediatric Hematology, Oncology and Immunology

Second phase of induction is one of 10 small molecule programs targeting Childhood Acute Lymphoblastic Leukemia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Childhood Acute Lymphoblastic LeukemiaActive, not recruiting

Childhood Acute Lymphoblastic LeukemiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

13 competitors in Childhood Acute Lymphoblastic Leukemia

#DrugCompanyPhaseTrials

Medrol

Pfizer

Approved

1 2

Fludara

Sanofi

Approved

—3

Cerubidine

HHikma Pharmaceuticals LLC

Approved

2 4

Cytoxan

BBaxter Healthcare Corporation

Monurol

Anerem

Idamycin

1 8

Velcade

SShilpa Grover, MD, MPH

Preclinical

1 9

Second phase of induction

FFederal Research Institute of Pediatric Hematology, Oncology and Immunology

Preclinical

1 10

Triple Intrathecal Therapy

RRutgers, The State University of New Jersey

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Childhood Acute Lymphoblastic Leukemia1 trial

Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015)

Unknown status·FFederal Research Institute of Pediatric Hematology, Oncology and Immunology·N/A·NCT03390387·4,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Second phase of induction. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Second phase of induction compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Second phase of induction. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Federal Research Institute of Pediatric Hematology, Oncology and Immunology company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: FFederal Research Institute of Pediatric Hematology, Oncology and Immunology

Second phase of induction

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Childhood Acute Lymphoblastic Leukemia1 trial

References

Drug Info

Quick Facts

Related News